Use of bicyclo(3.3.1)nonane-2,4,9-trione compounds with topoisomerase I and telomerase inhibiting and MAP kinase signal transduction regulating action for the preparation of medicaments for combating tumor or viral diseases

摘要

Use of bicyclo(3.3.1)nonane-2,4,9-trione compounds (i.e. clusianone and its derivatives) (I) in the production of medicaments for the prophylaxis and/or therapy of tumor and/or cancer diseases or viral diseases. Use of bicyclo(3.3.1)nonane-2,4,9-trione compounds (i.e. clusianone and its derivatives) of formula (I) and their salts, hydrates, isomers (specifically constitutional isomers, tautomers or stereoisomers), derivatives, prodrugs and/or metabolites in the production of medicaments for the prophylaxis and/or therapy of tumor and/or cancer diseases or viral diseases. R1-R5 = -COPh, -CH2CH=CMe2, -CH2CH2C(Me)=CH2, -CH2CH(C(Me)=CH2)-CH2CH=CMe2 or -CH2CH(C(Me)=CH2)-CH2CH2C(Me)=CH2. Provided that: (1) if one of R1, R2, R4 and R5 is COPh, then none of the other groups is -COPh; (2) one of the pairs R6/R7 and R8/R9 is Me2 and the other pair is H2. An Independent claim is also included for a pharmaceutical combination comprising (I) in combination with at least one other chemotherapeutic agent (II), specifically a protein kinase inhibitor, especially MAP kinase inhibitor.